Clinical Trial Update: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Loteprednol Etabonate 0.25% for prevention of corneal transplant rejection; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Edema
• Corneal Endothelial Dystrophy

Drugs mentioned

• Loteprednol Etabonate 0.25% (loteprednol etabonate)

Snippet

Sponsor: Price Vision Group | Conditions: Corneal Endothelial Dystrophy, Corneal Edema | Phase 4 | Status: COMPLETED | Results posted: 2024-08-14